The Trivalent Salmonella Conjugate Vaccine (TSCV), which simultaneously addresses typhoid fever and foodborne illness caused by non-typhoidal Salmonella enterica, elicited strong immune response in 100 percent of participants in the randomized, placebo-controlled clinical trial.
